Modifications of therapeutic proteins: challenges and prospects

The production of therapeutic proteins is one of the fastest growing sectors of the pharmaceutical industry. However, most proteins used in drug therapy require complex post-translational modifications for efficient secretion, drug efficacy and stability. Common protein modifications include variable glycosylation, misfolding and aggregation, oxidation of methionine, deamidation of asparagine and glutamine, and proteolysis. These modifications not only pose challenges for accurate and consistent bioprocessing, but also may have consequences for the patient in that incorrect modifications or aggregation may lead to an immune response to the protein therapeutic. This review provides examples of analytical and preventative advances that have been devised to meet these challenges, and insights into how further advances can improve the efficiency and safety in manufacturing recombinant proteins.

[1]  S. Frokjaer,et al.  Effects of sucrose on rFVIIa aggregation and methionine oxidation. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[2]  M. Butler,et al.  Effects of Ammonia and Glucosamine on the Heterogeneity of Erythropoietin Glycoforms , 2002, Biotechnology progress.

[3]  J. Blackburn,et al.  High affinity capture surface for matrix-assisted laser desorption/ionisation compatible protein microarrays. , 2003, Rapid communications in mass spectrometry : RCM.

[4]  A. Dickson,et al.  Endoplasmic reticulum signaling as a determinant of recombinant protein expression , 2003, Biotechnology and bioengineering.

[5]  D. Ejima,et al.  Review: Why is arginine effective in suppressing aggregation? , 2005, Protein and peptide letters.

[6]  N. Bulleid,et al.  The role of glutathione in disulphide bond formation and endoplasmic‐reticulum‐generated oxidative stress , 2006, EMBO reports.

[7]  P. Roach,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Insulin Lispro Mixtures , 2002, Clinical pharmacokinetics.

[8]  Gary Walsh,et al.  Post-translational modifications in the context of therapeutic proteins , 2006, Nature Biotechnology.

[9]  R. Gurny,et al.  Characterization of protein aggregation: the case of a therapeutic immunoglobulin. , 2007, Biochimica et biophysica acta.

[10]  Anne S De Groot,et al.  Immunomics: discovering new targets for vaccines and therapeutics. , 2006, Drug discovery today.

[11]  Anthony Mire-Sluis,et al.  Characterizing biological products and assessing comparability following manufacturing changes , 2004, Nature Biotechnology.

[12]  Douglas S Rehder,et al.  Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies. , 2005, Analytical chemistry.

[13]  Daniel I. C. Wang,et al.  Improvement of interferon-gamma sialylation in Chinese hamster ovary cell culture by feeding of N-acetylmannosamine. , 1998, Biotechnology and bioengineering.

[14]  Y. Lyubarskaya,et al.  Determination of protein oxidation by mass spectrometry and method transfer to quality control. , 2006, Journal of chromatography. A.

[15]  Angélica Meneses-Acosta,et al.  Heterogeneous conditions in dissolved oxygen affect N‐glycosylation but not productivity of a monoclonal antibody in hybridoma cultures , 2004, Biotechnology and bioengineering.

[16]  J. Moss,et al.  Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity. , 2000, The Journal of biological chemistry.

[17]  R J Harris,et al.  Heterogeneity of recombinant antibodies: linking structure to function. , 2005, Developments in biologicals.

[18]  Robert Gurny,et al.  High throughput screening of protein formulation stability: practical considerations. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[19]  C Russell Middaugh,et al.  Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice. , 2006, Journal of pharmaceutical sciences.

[20]  B. Kabakoff,et al.  Identification of multiple sources of charge heterogeneity in a recombinant antibody. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[21]  M. Manning,et al.  Stability of Human Serum Albumin During Bioprocessing: Denaturation and Aggregation During Processing of Albumin Paste , 2000, Pharmaceutical Research.

[22]  R B Freedman,et al.  Metabolic control of recombinant protein N-glycan processing in NS0 and CHO cells. , 2001, Biotechnology and bioengineering.

[23]  S. Elliott,et al.  Control of rHuEPO biological activity: the role of carbohydrate. , 2004, Experimental hematology.

[24]  J L Cleland,et al.  A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. , 2001, Journal of pharmaceutical sciences.

[25]  Samuel Moser,et al.  Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co‐expression of heterologous β1, 4‐N‐acetylglucosaminyltransferase III and Golgi α‐mannosidase II , 2006, Biotechnology and bioengineering.

[26]  G. Distefano,et al.  A new Chinese hamster ovary cell line expressing alpha2,6-sialyltransferase used as universal host for the production of human-like sialylated recombinant glycoproteins. , 2000, Biochimica et biophysica acta.

[27]  Johnny Gonzales,et al.  In vitro galactosylation of human IgG at 1 kg scale using recombinant galactosyltransferase. , 2005, Biotechnology and bioengineering.

[28]  Hongping Ye,et al.  Simultaneous determination of protein aggregation, degradation, and absolute molecular weight by size exclusion chromatography-multiangle laser light scattering. , 2006, Analytical biochemistry.

[29]  Anne Bertolotti,et al.  Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response , 2000, Nature Cell Biology.

[30]  Huub Schellekens,et al.  Structure-Immunogenicity Relationships of Therapeutic Proteins , 2004, Pharmaceutical Research.

[31]  J. Egrie,et al.  Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. , 2003, Experimental hematology.

[32]  Nigel Jenkins,et al.  Getting the glycosylation right: Implications for the biotechnology industry , 1996, Nature Biotechnology.

[33]  Uwe Kärst,et al.  Effects of buffering conditions and culture pH on production rates and glycosylation of clinical phase I anti-melanoma mouse IgG3 monoclonal antibody R24. , 2003, Biotechnology and bioengineering.

[34]  P. Friedl,et al.  Induction of protein aggregation in an early secretory compartment by elevation of expression level. , 2002, Biotechnology and bioengineering.